5-Nitro-2-furoic acid, also known as NF, is a heterocyclic compound containing a nitro group and a carboxylic acid group. It is a pale yellow solid that is soluble in water and organic solvents. NF has been studied for its potential therapeutic effects, including anti-inflammatory, antioxidant, and anticancer activities. It has been shown to inhibit the production of pro-inflammatory cytokines and reactive oxygen species. NF has also been shown to have cytotoxic effects on various cancer cell lines. Synthesis of NF typically involves the nitration of 2-furoic acid using nitric acid and sulfuric acid. Research into NF is ongoing, with studies focusing on its mechanism of action, potential therapeutic applications, and the development of novel NF-based drugs.'
5-nitro-2-furoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 12577 |
| CHEMBL ID | 1186 |
| SCHEMBL ID | 1221377 |
| MeSH ID | M0160481 |
| Synonym |
|---|
| 2-furoic acid, 5-nitro- |
| 2-furancarboxylic acid, 5-nitro- |
| nsc-6452 |
| nsc6452 |
| 645-12-5 |
| 5-nitro-2-furancarboxylic acid |
| nsc 6452 |
| nitrofurate |
| 5-nitropyromucate |
| ai3-23599 |
| 2-furancarboxylic acid, 5-nitro |
| brn 0139373 |
| einecs 211-432-6 |
| ccris 1197 |
| 5-nitrofurancarboxylic acid |
| 5-nitrofuroic acid |
| 5-nitro-2-furoic acid |
| 5-nitrofuran-2-carboxylic acid |
| OPREA1_282165 |
| 5-nitro-2-furoic acid, 98% |
| CHEMBL1186 |
| N0557 |
| 2-carboxy-5-nitrofuran |
| AKOS000119272 |
| STL164369 |
| AE-641/02433026 |
| uty7tn9ftp , |
| unii-uty7tn9ftp |
| AKOS015894363 |
| FT-0620695 |
| 5-nitro-furan-2-carboxylic acid |
| 5-nitro-2-furan-carboxylic acid |
| 5-nitro-2-furanoic acid |
| 5-nitro2-furanoic acid |
| SCHEMBL1221377 |
| 5-nitropyromucic acid |
| mfcd00003240 |
| DTXSID00214746 |
| F0001-1745 |
| F16228 |
| STR04789 |
| AMY7097 |
| 5-nitro-2-furan carboxylic acid |
| SY106223 |
| 5-nitro-2-furylcarboxylic acid |
| nitro-2-furoic acid, 5- |
| 5-nitro-2-furoicacid |
| EN300-17417 |
| Z56926611 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID100887 | Evaluated in vitro for antitrypanosomal activity against Leishmania infantum | 2002 | Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24 | Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. |
| AID1459827 | Inhibition of Trypanosoma cruzi trypanothione reductase at 100 uM using T(SH)2 as substrate at pH 7.5 in presence of NADPH by photometric method | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase. |
| AID1459831 | Anti-parasitic activity against Trypanosoma cruzi Dm28c epimastigotes in logarithmic phase assessed as morphological changes at 30 uM measured after 48 hrs by resazurin assay | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125 | Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase. |
| AID215328 | Evaluated in vitro for antitrypanosomal activity against Trypanosoma brucei | 2002 | Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24 | Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. |
| AID213632 | Evaluated in vitro for antitrypanosomal activity against Trypanosoma cruzi | 2002 | Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24 | Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. |
| AID106021 | Tested for cytotoxicity towards human MRC-5 cells | 2002 | Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24 | Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. |
| AID140480 | Tested for cytotoxicity towards mouse peritoneal macrophages (MPM) | 2002 | Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24 | Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.83) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||